畜禽用生物疫苗
Search documents
天康生物跌2.05%,成交额1.08亿元,主力资金净流出932.43万元
Xin Lang Cai Jing· 2025-10-22 06:13
Core Viewpoint - TianKang Biological experienced a stock price decline of 2.05% on October 22, 2023, with a current price of 7.65 CNY per share and a total market capitalization of 10.44 billion CNY [1] Company Overview - TianKang Biological Co., Ltd. was established on December 28, 2000, and listed on December 26, 2006. The company is located in Urumqi, Xinjiang, and its main business includes the production and sale of biological vaccines for livestock and poultry, feed, and plant protein, as well as pig breeding, pig farming, slaughtering, and meat product sales [1] - The revenue composition of TianKang Biological includes: 32.20% from the pig farming industry chain, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, 3.40% from other income, 0.29% from supplementary income, and 0.04% from guarantee fees [1] Financial Performance - For the first half of 2025, TianKang Biological achieved an operating income of 8.847 billion CNY, representing a year-on-year growth of 10.68%. The net profit attributable to the parent company was 338 million CNY, with a year-on-year increase of 22.27% [2] - Since its A-share listing, TianKang Biological has distributed a total of 1.891 billion CNY in dividends, with 598 million CNY distributed in the last three years [3] Shareholder Information - As of September 30, 2023, TianKang Biological had 60,600 shareholders, a decrease of 3.42% from the previous period. The average circulating shares per person increased by 3.54% to 22,542 shares [2] - The top ten circulating shareholders include notable institutional investors such as Guotai Junan Zhongzheng Livestock Breeding ETF and Harvest Agricultural Industry Stock A, with significant increases in their holdings [3]
天康生物涨2.09%,成交额2.56亿元,主力资金净流入1454.63万元
Xin Lang Cai Jing· 2025-10-17 05:58
Core Viewpoint - TianKang Biological has shown a positive stock performance with a year-to-date increase of 23.70% and a market capitalization of 10.69 billion yuan as of October 17 [1] Company Overview - TianKang Biological Co., Ltd. is located in Urumqi, Xinjiang, and was established on December 28, 2000, with its stock listed on December 26, 2006 [1] - The company specializes in the production and sales of biological vaccines for livestock and poultry, feed, and plant protein, as well as pig breeding, pig farming, slaughter processing, and meat product sales [1] Financial Performance - For the first half of 2025, TianKang Biological achieved an operating income of 8.847 billion yuan, representing a year-on-year growth of 10.68%, and a net profit attributable to shareholders of 338 million yuan, up 22.27% year-on-year [2] - Cumulatively, the company has distributed 1.891 billion yuan in dividends since its A-share listing, with 598 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, the number of shareholders for TianKang Biological was 60,600, a decrease of 3.42% from the previous period, with an average of 22,542 circulating shares per shareholder, an increase of 3.54% [2] - The top ten circulating shareholders include notable funds such as Guotai Zhongzheng Livestock Breeding ETF and Jiashi Agricultural Industry Stock A, with increases in their holdings [3]
天康生物跌2.01%,成交额5750.80万元,主力资金净流出455.36万元
Xin Lang Cai Jing· 2025-09-30 02:02
Core Points - TianKang Bio's stock price has increased by 15.48% year-to-date, but has seen a decline of 2.66% in the last five trading days [2] - The company reported a revenue of 8.847 billion yuan for the first half of 2025, representing a year-on-year growth of 10.68%, with a net profit of 338 million yuan, up 22.27% [2] - The company has distributed a total of 1.891 billion yuan in dividends since its A-share listing, with 598 million yuan distributed in the last three years [3] Company Overview - TianKang Bio, established on December 28, 2000, and listed on December 26, 2006, is located in Urumqi, Xinjiang, and specializes in the production and sales of biological vaccines for livestock, feed, and plant protein [2] - The revenue composition of TianKang Bio includes 32.20% from the pig breeding industry chain, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [2] - As of September 19, 2025, the number of shareholders is 62,700, a decrease of 9.64% from the previous period, with an average of 21,770 circulating shares per person, an increase of 10.67% [2] Institutional Holdings - As of June 30, 2025, the sixth largest circulating shareholder is Guotai Zhongzheng Livestock Breeding ETF, holding 15.5491 million shares, an increase of 641,000 shares from the previous period [3] - The ninth largest circulating shareholder is Harvest Agricultural Industry Stock A, holding 10.2945 million shares, an increase of 630,100 shares [3] - The tenth largest circulating shareholder is Southern Zhongzheng 1000 ETF, holding 10.0839 million shares, an increase of 1.8978 million shares [3]
天康生物涨2.12%,成交额2.53亿元,主力资金净流入1201.34万元
Xin Lang Zheng Quan· 2025-09-19 03:30
Core Viewpoint - TianKang Biological has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth in the agricultural and livestock sector [1][2]. Company Overview - TianKang Biological Co., Ltd. is located in Urumqi, Xinjiang, and was established on December 28, 2000, with its stock listed on December 26, 2006. The company specializes in the production and sales of biological vaccines for livestock, feed, and plant protein, as well as pig breeding, pig farming, slaughter processing, and meat product sales [1]. - The revenue composition of TianKang Biological includes: 32.20% from pig farming, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [1]. Financial Performance - For the first half of 2025, TianKang Biological achieved an operating income of 8.847 billion yuan, representing a year-on-year growth of 10.68%. The net profit attributable to the parent company was 338 million yuan, reflecting a year-on-year increase of 22.27% [2]. - Since its A-share listing, TianKang Biological has distributed a total of 1.891 billion yuan in dividends, with 598 million yuan distributed over the past three years [3]. Shareholder Information - As of September 10, 2025, the number of shareholders of TianKang Biological was 69,400, an increase of 1.60% from the previous period. The average number of circulating shares per person decreased by 1.57% to 19,672 shares [2]. - Notable institutional shareholders include Guotai Zhongzheng Livestock Breeding ETF, which holds 15.5491 million shares, and Jiashi Agricultural Industry Stock A, holding 10.2945 million shares, both of which have increased their holdings compared to the previous period [3].